The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1

    May 2024 in “ New England Journal of Medicine ”
    Vasileios Oikonomou, Grace Smith, Gregory Constantine … Michail S. Lionakis
    Studysummary This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on escholarship.org →
    Discuss this study in the Community →

    Research cited in this study 2

    1. AIRE Deficiency Leads to the Development of Alopecia Areata-Like Lesions in Mice ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2022
    2. Autoimmune Polyendocrine Syndrome Type 1: An Italian Survey on 158 Patients Journal of endocrinological investigation · 2021